European Pharmaceutical Review

DECEMBER 9, 2022

According to a new market report by ResearchAndMarkets, the global oligonucleotide synthesis market is projected to reach $16.7 billion by 2027 during the forecast period, due to the rise in ongoing clinical trials for oligonucleotide-based therapies in key therapeutic sectors such as oncology. Synthesised oligonucleotides.

Compounding 83

Compounding 83

PharmaShots

MAY 19, 2023

Alimera Acquires Rights from EyePoint Pharmaceuticals to Commercialise Yutiq in the US Date: May 19, 2023 | Tags: Alimera, EyePoint Pharmaceuticals, Yutiq, Iluvien, chronic non-infectious uveitis, US, Pharma Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A Date: May 19, 2023 | Tags: Sobi, Efanesoctocog Alfa, (..)

Medical Schools 40

Medical Schools FDA Immunization Vaccines 40

Roots Analysis

SEPTEMBER 13, 2023

These molecules can be conjugated with various modalities, such as haptens, enzymes, isotopes, fluorescent tags, carrier proteins, polymers, particle conjugates and photoreactive molecules. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.

Labelling 40

Labelling 40

European Pharmaceutical Review

NOVEMBER 10, 2022

Complex medicines include a variety of advanced drug chemistries and therapeutic targeting vehicles, comprising complex APIs eg, antibody-drug conjugates , oligonucleotide conjugates, complex formulations eg nanomedicines, or complex routes of delivery. Figure 1 : The proposed Medicines Discovery Catapult classification of complex medicines.

Labelling 92

Labelling Compounding 92